A rare biotech IPO lands on Nas­daq, boost­ed by RA Cap­i­tal and a for­mer Eli Lil­ly drug

An­oth­er biotech backed by RA Cap­i­tal Man­age­ment is mak­ing the Nas­daq jump Tues­day, brav­ing the cold bear mar­ket wa­ters.

Acrivon Ther­a­peu­tics priced its IPO at …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER